Zenith Healthcare reported a net profit of Rs 0.02 crore for the quarter ended September 30, 2026, marking a decline from Rs 0.14 crore in the previous quarter. The company also provided an update on its ongoing amalgamation with Achyut Healthcare, noting that the share exchange ratio of 119:50 remains subject to regulatory and NCLT approvals.
Zenith Healthcare Reports Q2 FY2027 Financial Results
Net profit reached Rs 0.02 crore for the period ended September 30, 2026.
Revenue from operations stood at Rs 2.01 crore for the second quarter.
Reader Takeaway: The company faces a sequential profit decline while the proposed merger awaits key regulatory and NCLT clearances.
What just happened
Zenith Healthcare has released its financial results for the quarter and half-year ended September 30, 2026. The company posted a net profit of Rs 0.02 crore, down from Rs 0.14 crore in the preceding June quarter. Revenue from operations also saw a contraction, coming in at Rs 2.01 crore compared to Rs 3.43 crore in the first quarter of the fiscal year.
Why this matters
The financial results highlight a challenging quarter with declining top and bottom-line figures. Investors are now shifting focus toward the company's corporate restructuring plans, specifically the proposed amalgamation with Achyut Healthcare Limited. This merger is intended to reorganize the business structure but has not yet been reflected in the current financial statements.
Corporate Developments
The board has reaffirmed its commitment to the Scheme of Amalgamation of Achyut Healthcare Limited with Zenith Healthcare. Key details include:
- A share exchange ratio of 119:50 (119 shares of Zenith for every 50 shares of Achyut).
- The scheme remains subject to pending approvals from the BSE, shareholders, creditors, and the NCLT.
- No financial impact of the merger has been recognized in these results.
Auditor and Governance
Doshi Doshi & Co, the statutory auditors, conducted a limited review and issued an unmodified report, confirming the financials comply with Ind AS standards.
What to track next
Shareholders should monitor upcoming filings regarding NCLT hearing dates and approvals from statutory authorities, which will dictate the timeline for the amalgamation and the subsequent impact on the equity capital structure.
